Secondaries announced 1.3.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Clovis Oncology
Symbol: CLVS
Price: Last trade $44.42
Trade Date: 1/4
Shares: 3.9 million
Underwriter(s)J.P. Morgan, BofA Merrill Lynch, Stifel
Co Manager(s)SunTrust Robinson Humphrey
Rating=Subscription Needed